Table III.
AMD risk for all AMD based on genotype and CEP markers
Odds ratios were determined for all AMD risk based on genotype alone or based on the joint effect of genotype plus elevated levels of both CEP markers relative to median control levels (≥19 pmol/ml CEP adducts and ≥1.3 CEP autoantibody titer). Odds ratios and 95% CI involving CEP markers are based on log-transformed concentrations.
| AMD risk genotype | Genotype frequency (%)
|
Odds ratio (95% CI)
|
|||
|---|---|---|---|---|---|
| Control | AMD | Genotype only | Joint effect CEP adducts and autoantibodies
|
||
| Not both elevated | Both elevated | ||||
| ARMS2 | n = 404 | n = 708 | |||
| GG | 246 (60.9%) | 278 (39.3%) | 1.00 (reference) | 1.00 (reference) | 2.75 (1.92, 3.95) |
| GT | 143 (35.4%) | 306 (43.2%) | 1.89 (1.46, 2.46) | 1.87 (1.32, 2.65) | 4.82 (3.26, 7.14) |
| TT | 15 (3.7%) | 124 (17.5%) | 7.32 (4.17, 12.84) | 6.16 (3.00, 12.66) | 20.88 (8.22, 53.04) |
| HTRA1 | n = 229 | n = 747 | |||
| GG | 134 (58.5%) | 294 (39.4%) | 1.00 (reference) | 1.00 (reference) | 2.90 (1.84, 4.57) |
| GA | 78 (34.1%) | 279 (37.3%) | 1.63 (1.18, 2.25) | 1.90 (1.26, 2.86) | 3.23 (2.01, 5.18) |
| AA | 17 (7.4%) | 174 (23.3%) | 4.66 (2.72, 7.99) | 4.21 (2.06, 8.60) | 10.61 (4.74, 23.71) |
| CFH | n = 381 | n = 788 | |||
| TT | 161 (42.3%) | 160 (20.3%) | 1.00 (reference) | 1.00 (reference) | 2.55 (1.62, 4.02) |
| TC | 172 (45.1%) | 384 (48.7%) | 2.25 (1.69, 2.98) | 2.19 (1.50, 3.20) | 6.17 (4.03, 9.45) |
| CC | 48 (12.6%) | 244 (31.0%) | 5.12 (3.50, 7.47) | 6.13 (3.74, 10.06) | 10.65 (5.90, 19.20) |
| C3 | n = 343 | n = 769 | |||
| CC | 198 (57.7%) | 317 (41.2%) | 1.00 (reference) | 1.00 (reference) | 2.84 (1.96, 4.13) |
| CG | 114 (33.2%) | 270 (35.1%) | 1.48 (1.12, 1.96) | 1.62 (1.11, 2.34) | 3.71 (2.43, 5.68) |
| GG | 31 (9.1%) | 182 (23.7%) | 3.67 (2.41, 5.58) | 4.52 (2.69, 7.60) | 8.87 (4.28, 18.37) |